文献速递血栓与止血

CB 2679d-GT:一种效力高于Padua变异体的新型凝血因子IX基因治疗

Gene therapy for hemophilia B using CB 2679d-GT: a novel factor IX variant with higher potency than factor IX Padua.
PubMed 文献 · Blood · 2021-01-01

本研究在血友病B小鼠中比较了新型凝血因子IX变异体CB 2679d-GT(含R318Y、R338E、T343R三个氨基酸替换)与R338L-Padua变异体经AAV载体基因治疗后的效果。结果显示CB 2679d-GT的凝血活性较R338L-Padua显著提高约三倍,出血时间和总失血量显著减少,且FIX表达至少维持20周,免疫原性未显著增加。

要点

  • CB 2679d-GT在血友病小鼠中凝血活性较R338L-Padua提高约三倍。
  • CB 2679d-GT显著缩短出血时间(约五至八倍)并减少总失血量(约四倍)。
  • 两种变异体FIX表达均维持至少20周,免疫原性未见显著增加。

核心结论

  • CB 2679d-GT在AAV基因治疗后表现出优于R338L-Padua的凝血活性和止血效果。

研究设计与样本

  • 在血友病小鼠中开展基于AAV载体的基因治疗研究,比较CB 2679d-GT与R338L-Padua。

主要发现

  • CB 2679d-GT的凝血活性较R338L-Padua显著提高约三倍。
  • CB 2679d-GT使出血时间缩短约五至八倍,总失血量减少约四倍。
  • CB 2679d-GT和R338L-Padua的FIX表达均维持至少20周。
  • CB 2679d-GT的免疫原性未显著增加。

临床怎么用

  • CB 2679d-GT有望在血友病B患者中实现更高FIX活性水平和更优止血疗效,并可能降低载体剂量相关毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sustained expression of therapeutic factor IX (FIX) levels has been achieved after adeno-associated viral (AAV) vector-based gene therapy in patients with hemophilia B. Nevertheless, patients are still at risk of vector dose-limiting toxicity, particularly liver inflammation, justifying the need for more efficient vectors and a lower dosing regimen. A novel increased potency FIX (designated as CB 2679d-GT), containing 3 amino acid substitutions (R318Y, R338E, T343R), significantly outperformed the R338L-Padua variant after gene therapy. CB 2679d-GT demonstrated a statistically significant approximately threefold improvement in clotting activity when compared with R338L-Padua after AAV-based gene therapy in hemophilic mice. Moreover, CB 2679d-GT gene therapy showed significantly reduced bleeding time (approximately fivefold to eightfold) and total blood loss volume (approximately fourfold) compared with mice treated with the R338L-Padua, thus achieving more rapid and robust hemostatic correction. FIX expression was sustained for at least 20 weeks with both CB 2679d-GT and R338L-Padua whereas immunogenicity was not significantly increased. This is a novel gene therapy study demonstrating the superiority of CB 2679d-GT, highlighting its potential to obtain higher FIX activity levels and superior hemostatic efficacy following AAV-directed gene therapy in hemophilia B patients than what is currently achievable with the R338L-Padua variant.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Nair N, De Wolf D, Nguyen PA, et al. Gene therapy for hemophilia B using CB 2679d-GT: a novel factor IX variant with higher potency than factor IX Padua. Blood. 2021. PMID: 33735915. doi:10.1182/blood.2020006005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。